LifeCore Biomedical registers resale of 20.5M shares by selling stockholders; company gets no proceeds

Filed September 30, 2025 · ~1 min read

Key Changes

• high

  The prospectus covers resale of up to 20,456,637 shares by selling stockholders, including 6,556,521 outstanding common shares and 13,900,116 shares issuable upon conversion of Series A Convertible Preferred Stock.

  The Offering verify on EDGAR →
• high

  LifeCore Biomedical is not selling any shares and will not receive any proceeds from the sale; all proceeds go to the selling stockholders.

  The Offering verify on EDGAR →
• medium

  The company has agreed to reimburse selling stockholders up to $105,000 for registration expenses, a cost borne despite receiving no offering proceeds.

  The Offering verify on EDGAR →